Abstract 16132: Effectiveness of Adaptive Servo-Ventilation Therapy in NYHA-IV Heart Failure Patients
Introduction: Adaptive servo-ventilation (ASV) therapy is considered clinically beneficial to patients with heart failure (HF). On the other hands, large proportion of patients who are scheduled for ASV therapy are serious HF, and they are resistant to medication therapy. Some of them do not respond to ASV therapy. We aimed to identify the effectiveness of ASV therapy in serious HF patients.
Methods: After medical therapy was optimized, a 6-months follow up study was conducted of 95 patients with NYHAIV HF. The patients were classified into two groups, which were ASV therapy group (56 patients, 74.9 ± 10.1 years, 31 male) and non-ASV therapy group (39 patients, 78.5 ± 8.6 years, 24 male). The incidence of fatal cardiovascular events including death from progression of HF, fatal cardiac arrhythmias was tracked.
Results: No significant differences were observed between two groups with regard to age, gender, body mass index, drug therapy, cardiovascular risk factors, left ventricular ejection fraction (ASV therapy group: 39.1 ± 18.7 %, non-ASV therapy group: 34.8 ± 16.0 %, p= 0.27 ) , brain natriuretic peptide level (ASV therapy group: 945.0 ± 823.9 pg/ml, non-ASV therapy group: 1264.6 ± 921.8 pg/ml, p= 0.10 ). After 6-months follow up, the survival rate calculated using Kaplan-Meier analysis was significantly higher in ASV therapy group than in non-ASV therapy group (p= 0.0001 , log rank test) (Figure 1).
Conclusions: Our results suggest that ASV improves prognosis in NYHAIV HF patients.
Author Disclosures: T. Kato: None. N. Takama: None. M. Kurabayashi: None.
- © 2014 by American Heart Association, Inc.